About Lilly Diabetes
For more than 90 years, Lilly Diabetes has been committed to meeting the needs of people affected by diabetes with treatment options, support programs and more. We believe science is most valuable when it is connected to the people who can use it. This belief has inspired Lilly since 1923 when we introduced the world’s first commercial insulin. For more information, visit www.lillydiabetes.com
At Sanofi Diabetes, our priorities are focused on the needs of people with diabetes around the world. With a century of experience in this area, we strive to help people manage the complex challenge of diabetes by delivering a range of innovative, personalized solutions integrated across diagnostics, therapies, devices and services. Because we understand the daily impact of diabetes and our patients' aspirations, we know how to improve their quality of life. We want people to live 'beyond' diabetes, to achieve aspirations and to make the most of everyday!
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. We are offering one of the broadest portfolios of diabetes products in the industry and are a supplier of nearly half of the world’s insulin with 29.2 million people using its products. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, hemophilia and growth disorders.
Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries.
Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world. We aim to lead in all disease areas in which we are active.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
MSD products has been present for over 30 years in the GULF region through its local distributors in the UAE, Kuwait, Bahrain, Qatar & Oman and MSD ranks amongst the leading pharmaceutical companies in the region. MSD provides innovative medications in several therapeutic areas, including Anti- Infectives, Cardiovascular, Asthma & Allergy, Diabetes, HCV, HIV, Pain & Inflammation, Osteoporosis, Oncology, Fertility, Ophthalmic, and Anesthesia in addition to several specialized Vaccines.
For more information, visit www.msd.com and connect with us on Facebook, LinkedIn and Twitter at MSD GCC.
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com .
For More information About Boehringer Ingelheim:
Follow us on:
Facebook : https://www.facebook.com/BoehringerMEA/
Twitter : https://twitter.com/BoehringerMEA
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
Les Laboratoires Servier is the leading French independent pharmaceutical company established in 1954. Servier is present in 140 countries, with a scientific office in Dubai and offices across the Gulf region.
Servier is committed to developing innovative and novel drugs that address major public health problems and provide objective therapeutic benefits. With more than 20,000 employees worldwide, including nearly 3,000 in Research and Development, and almost 25% of turnover re-invested in research, one of the world's highest ratios of investment in R&D.
As a global leader in medical technology, we improve the lives and health of millions of people each year — with our innovative therapies, services, and solutions.
Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people’s lives. With challenges facing families and healthcare systems — such as rising costs, aging populations, and the burden of chronic disease — we are using the power of technology to take healthcare Further, Together.
Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value — for healthcare systems, providers, and the people they serve. Learn more at Medtronic.com.
For 40 years, Hikma has been developing, manufacturing and marketing branded generic medicines in the MENA region. We supply quality branded generics to 17 markets and have a proven track record with in-licensors. We are also building our injectable medicines business in the territory. Our long-standing presence in the MENA has made us the fifth largest pharmaceutical manufacturer in the region and we have US FDA inspected facilities in Jordan and Saudi Arabia.
As a leading licensing partner globally. Since the early 1980s, we have grown to build a successful track record with global licensing partners. Our partners collaborate with us because of our reputation for quality, our strong brand recognition, and our US FDA inspected manufacturing facilities. Organizations we work with know they can rely on us to deliver consistently, in every market, all over the world
We're helping to shape a healthier world that enriches all of our communities.
Better health, Within reach, Everyday…
HELPING PEOPLE LIVE THEIR BEST LIVES THROUGH BETTER HEALTH
For more than 125 years, Abbott Laboratories has adapted to an increasingly complex healthcare environment by keeping its focus where it belongs—on helping people achieve their best possible health, in all stages of life, around the world.
Abbott has a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and generic pharmaceuticals, serving people in more than 150 countries.
In Diabetes Care, Abbott is constantly improving the glucose monitoring process with diabetes products that are easy to use and highly accurate through innovative product development programs and many cutting-edge glucose monitoring technologies.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.
Eva Pharma founded over a decade ago. Eva Pharma has become one of the leading generic pharmaceutical manufacturers in the MENA region, providing over 120 pharmaceutical products. Eva Pharma consists of a team of 2600 loyal staff and produces an average 300,000 effective and affordable packs of medicine daily from 126 different products.
Pic Solution & HTL-Strefa is a global market leader in safety lancets, personal lancets and pen needles, expanding also in consumer health products.
The pen needle portfolio of Pic Solution, leading Italian diabetes care brand, includes Insupen 33Gx4mm, representing the excellence of its extremely wide range (from 32G to 29G). The Extr3me sharpening technology and High Flow Thin Wall make Insupen pen needles easy to use and comfortable.
HTL-Strefa is a world's leading medical device company that develops and manufactures mainly safety lancets and safety pen needles. Its modern manufacturing process and 20 years of experience on the global market allow to successfully ensure safety and convenience and meet evolving needs of both patients and health care professionals.
SBI Neopharma is a joint venture between SBI Pharmaceuticals Co. Ltd. and Neopharma LLC for the research, production and global sales for medicines, medical devices, cosmetics and health foods utilizing 5-ALA (5-aminolevulinic acid). SBI Pharmaceuticals is part of the SBI group, a Tokyo based financial services organization with varied business interests. Neopharma is a UAE based global pharmaceutical company founded by Dr. B.R. Shetty.
With a vision to create a world without limits for people with diabetes, LifeScan, Inc. is a world leader in blood glucose monitoring – globally more than 20 million people depend on the company’s OneTouch® brand products to help them manage their diabetes. The LifeScan portfolio includes personal blood glucose meters, testing strips, lancets, point of care testing systems and integrated digital solutions.
For over 35 years LifeScan has developed products defined by simplicity, accuracy and trust. Recent innovations in OneTouch® range of meter is ColorSure® technology that instantly shows when patients’ blood glucose results are in or out of range, and built-in Bluetooth®[i] Smart Technology that enables the meters to connect wirelessly and sync seamlessly with the OneTouch Reveal® mobile app
For Sponsorship and Exhibition inquiries, please contact firstname.lastname@example.org
Emirates Diabetes & Endocrine Congress (EDEC) is organized by Emirates Diabetes Society. EDEC is the region's premier platform to update attendees on the recent advances in the ever-changing field of diabetes and endocrine diseases.
|MCI Middle East |
United Arab Emirates
Tel: +971 4 311 6300
Fax: +971 4 311 6301